Neoleukin Therapeutics, Inc.
NASDAQ: NLTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Donna M. Cochener-Metcalfe
- Employees
- 7
- Headquarters
- Seattle, United States
- IPO year
- 2014
- Market cap
- $8.2M
- Website
- https://www.neoleukin.com
Loading NLTX…
Loading profile data…Frequently asked questions about NLTX
What does Neoleukin Therapeutics, Inc. (NLTX) do?
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to e...
Where does NLTX trade?
Neoleukin Therapeutics, Inc. (NLTX) trades on the NASDAQ Global Market.
What sector is NLTX in?
Neoleukin Therapeutics, Inc. (NLTX) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Neoleukin Therapeutics, Inc.?
Donna M. Cochener-Metcalfe is the chief executive officer of Neoleukin Therapeutics, Inc. (NLTX).
Where is Neoleukin Therapeutics, Inc. headquartered?
Neoleukin Therapeutics, Inc. is headquartered in United States.
Does NLTX pay a dividend?
Neoleukin Therapeutics, Inc. (NLTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NLTX go public?
Neoleukin Therapeutics, Inc. (NLTX) completed its initial public offering in 2014.